Evidence map›Paper›PMID 37202742›Full record

ArticleBMC cancer2023

LncRNA-PVT1 was identified as a key regulator for TMZ resistance and STAT-related pathway in glioma.

Yusheng Chen, Fengjin Ma, Zhe Zhang, Yang Guo, Hanwei Shen, Hang Chen

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 4 institutions in 1 country.

Yusheng ChenDepartment of Neurosurgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, No.7 WeiWu Street, 450003, Zhengzhou, Zhengzhou, China.
Fengjin MaDepartment of Intensive Care Unit, The Third People's Hospital of Zhengzhou, Zhengzhou, China.
Zhe ZhangDepartment of Neurosurgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, No.7 WeiWu Street, 450003, Zhengzhou, Zhengzhou, China.
Yang GuoDepartment of Neurosurgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, No.7 WeiWu Street, 450003, Zhengzhou, Zhengzhou, China.
Hanwei ShenDepartment of Neurosurgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, No.7 WeiWu Street, 450003, Zhengzhou, Zhengzhou, China.
Hang ChenDepartment of Neurosurgery, Henan Provincial People's Hospital, People's Hospital of Zhengzhou University, People's Hospital of Henan University, No.7 WeiWu Street, 450003, Zhengzhou, Zhengzhou, China. chenh413@126.com.
Henan University · CNZhengzhou University · CNHenan Provincial People's Hospital · CNZhengzhou People's Hospital · CN

Funding

Science and Technique Foundation of Henan Province No. 222102310056
6 · The paper itself

Abstract

backgroundPVT1, a previously uncharacterized lncRNA, was identified as a critical regulator involved in multiple functions in tumor, including cell proliferation, cell motility, angiogenesis and so on. However, the clinical significance and underlying mechanism of PVT1 was not be fully explored in glioma.

methodsIn this study, 1210 glioma samples with transcriptome data from three independent databases (CGGA RNA-seq, TCGA RNA-seq and GSE16011 cohorts) were enrolled in this study. Clinical information and genomic profiles containing somatic mutations and DNA copy numbers were collected from TCGA cohort. The R software was performed for statistical calculations and graphics. Furthermore, we validated the function of PVT1 in vitro.

resultsThe results indicated that higher PVT1 expression was associated with aggressive progression of glioma. Cases with higher PVT1 expression always accompanied by PTEN and EGFR alteration. In addition, functional analyses and western blot results suggested that PVT1 inhibited the sensitivity of TMZ chemotherapy via JAK/STAT signaling. Meanwhile, knockdown of PVT1 increased the sensitivity of TZM chemotherapy in vitro. Finally, high PVT1 expression was associated with reduced survival time and may serve as a strong prognostic indicator for gliomas.

conclusionsThis study demonstrated that PVT1 expression strongly correlated with tumor progression and chemo-resistance. PVT1 may become a potential biomarker for the diagnosis and treatment in glioma.

Indexed as

Drug Resistance, NeoplasmGene Expression Regulation, NeoplasticGliomaRNA, Long NoncodingTemozolomideAdultBiomarkers, TumorCarcinogenesisCell Line, TumorFemaleGene Knockdown TechniquesHumansJanus KinasesMaleMiddle AgedSTAT Transcription FactorsBiomarkers, TumorJanus KinasesPVT1 long-non-coding RNA, humanRNA, Long NoncodingSTAT Transcription FactorsTemozolomideChemoresistanceGliomaJAK/STATPVT1Survival

Identifiers

PMID37202742
PMCPMC10197392
OpenAlexW4377047188

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.